Tecan and Enigma Diagnostics sign global manufacturing and supply agreement for point-of-care Molecu
(Thomson Reuters ONE) - Tecan Group AG / Tecan and Enigma Diagnostics sign global manufacturing and supply agreement for point-of-care Molecular Diagnostics instruments processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. * Tecan to industrialize and supply commercially manufactured Diagnostics instruments * First demonstration instruments delivered * Commercial launch of Enigma ML for initial use is anticipated in Q4 2010M?edorf, Switzerland and Oxford, UK, February 5, 2010 - The Tecan Group (SIXSwiss Exchange: TECN), a leading global provider of laboratory instruments andsolutions, and Enigma Diagnostics Limited, the decentralised and point-of-caremolecular diagnostics company, announced today the signing of a manufacturingand supply agreement for Enigma's ML instruments. Under the agreement, Tecanwill industrialize and deliver commercially manufactured ML instruments forEnigma's global market supplies for an initial five-year contract and will alsomanage the ML instrument's supply chain. The first ML demonstration instrumentshave been delivered for Enigma's GlaxoSmithKline delivery commitments forpoint-of-care molecular diagnostic influenza tests.The launch of Enigma ML and supply of commercial series systems for its initialuse to identify specific influenza virus strains is anticipated in Q4 2010,subject to successful clinical trials and regulatory approval. Enigma will alsoadd additional tests for other areas such as infectious disease management tothe ML system test menu in the future.Financial details of the agreement were not disclosed.John McKinley, Chairman and CEO of Enigma, said: "This is a milestone agreementfor Enigma. We chose Tecan for its leading reputation as a developer andmanufacturer of commercial medical instruments and its global range of technicaland support services network. This represents the first of a number of potentialadditional agreements relating to Tecan's support of the Enigma ML system."Thomas Bachmann, CEO of Tecan, said: "We are excited to be partnering with suchan innovative company as Enigma. We are highly committed to contributing to thesuccess of the wide range of potential applications and tests the ML instrumentplatform offers with our experience in manufacturing and servicing high qualityand regulatory compliant diagnostic products. The dedicated and modular MLinstrument marks a breakthrough in point-of-care molecular diagnostics."About the Enigma ML InstrumentThe Enigma ML instrument delivers fully-automated results from swab samples inless than 60 minutes at the point of care and to the same accuracy standards asreference laboratories. This will mean that patients can be tested for a broadrange of diseases including specific influenza subtypes in the community andreceive appropriate treatment rapidly. Currently the existing network ofgovernment diagnostic laboratories, staffed by specialist operators, can oftentake several days before the results of tests are known. Operators of the EnigmaML system will not require specialist training.About TecanTecan (www.tecan.com) is a leading global provider of laboratory instruments andsolutions in biopharmaceuticals, forensics, and clinical diagnostics. Thecompany specializes in the development, production and distribution ofautomation solutions for laboratories in the life sciences sector. With itssubsidiary REMP (www.remp.com), Tecan is the market leader in automatedlaboratory storage and logistics systems. Its clients include pharmaceuticaland biotechnology companies, university research departments, forensic anddiagnostic laboratories. As an original equipment manufacturer, Tecan is also aleader in developing and manufacturing OEM instruments and components that arethen distributed by partner companies. Founded in Switzerland in 1980, thecompany has manufacturing, research and development sites in both Europe andNorth America and maintains a sales and service network in 52 countries.In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange(TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).About Enigma Diagnostics LimitedEnigma Diagnostics Limited specialises in developing next generation rapidmolecular diagnostic instrument platforms for decentralized and point-of-caresettings.Enigma's innovative and proprietary technology combines the speed andsensitivity of real-time PCR (polymerase chain reaction) with the simplicityneeded for decentralized and point-of-care testing providing results from a rawsample in less than 60 minutes. The Company is targeting a number ofmulti-billion pound markets, core among which are the Clinical and high-valueApplied Markets. Enigma's commercialisation strategy is to maximize revenuesfrom a continuous flow of market leading rapid diagnostic point-of- careinstrument and assay platforms, based on unique technologies and underpinned byits broad Intellectual Property portfolio. Enigma will partner with marketleaders where global penetration of markets is required and where appropriate,will engage regional partners and build in-house sales and marketing capabilityto direct distribution of its products.For more information visit www.enigmadiagnostics.com
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Panoro Minerals Retains Ascenta Capital Partners for Investor RelationsDatum: 05.02.2010 - 07:25 Uhr
Sprache: Deutsch
News-ID 12101
Anzahl Zeichen: 0
contact information:
Town:
Männedorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Tecan and Enigma Diagnostics sign global manufacturing and supply agreement for point-of-care Molecu"
steht unter der journalistisch-redaktionellen Verantwortung von
Tecan Group AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
